Medpace Holdings, Inc. (MEDP) Q3 Revenue Up 8.5%, EPS $4.84; Launches $1B Buyback
Medpace (MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and GAAP EPS of $4.84. Backlog increased to $3.17B, and the company launched a $1B buyback program. 2026 guidance was reaffirmed at $2.835B–$2.855B revenue and GAAP net income of $514M–$524M.
How this was made
The 30-second read
Why it matters
The combination of a reported Q3 beat-style datapoint (revenue growth and EPS), higher backlog ($3.17B), reaffirmed 2026 guidance, and a new $1.0B repurchase authorization creates multiple near-term valuation supports.
Market read
Traders can reassess near-term expectations for CRO demand and capital return based on the fresh quarterly results and the newly authorized repurchase.
What to watch
The article does not quantify buyback timing, execution pace, or any margin commentary, so traders may need to verify whether EPS quality and cash flow back the buyback capacity.
Background
Medpace is a CRO, and the article frames the quarter as continuation of multi-year growth and margin expansion, with backlog supporting 2026 targets.
Ticker impact
Medpace reported Q3 2026 revenue of $716.0M (+8.5% YoY) and GAAP EPS of $4.84, alongside a new $1.0B buyback authorization.
Likely upward bias as investors price in sustained CRO demand plus increased buyback support.
The article discloses a fresh quarterly print (revenue, EPS), reaffirmed 2026 guidance, and a new, sizable repurchase authorization, all of which are direct valuation catalysts.
Market effects
Reinforces the CRO growth and margin-expansion narrative, potentially improving sentiment toward other contract research organizations.
Primarily US large-cap sentiment; limited direct regional spillover beyond healthcare services.
Modest, as CRO demand is globally driven but the disclosed catalysts are company-specific.
Counterpoint
Buyback enthusiasm may be partially offset if backlog conversion or book-to-bill weakens, making the guidance reaffirmation less durable than the headline suggests.
Key entities
- companyMedpace Holdings, Inc.
Reported Q3 2026 revenue $716.0M (+8.5% YoY), GAAP EPS $4.84, backlog $3.17B, reaffirmed 2026 guidance, and approved up to $1.0B buyback.
